1. Scrip
  2. >>R&D
  3. >>Clinical Trials

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

BiTEs Bring New Side Effects To Solid Tumor Setting

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Health care and medical technology services concept. Medical worker using data virtual with health care icons, medical technology background, health insurance business.
Bispecific T-cell engagers require new safety protocols in treating solid tumors • Source: Shutterstock

Amgen, Inc.’s Imdelltra (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) is one of only two bispecific T-cell engagers (BiTEs) approved in the US to treat solid tumors. As additional DLL3-targeting BiTEs near the market, those drugs may benefit from doctors’ earlier experience learning to manage adverse events for BiTEs and other T-cell recruiters – chiefly cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)

Key Takeaways

  • Data for DLL3-targeting bispecific T-cell engagers (BiTEs) – Amgen’s Imdelltra, Boehringer’s obrixtamig and Merck/Daiichi’s MK-6070 – show efficacy that may best the standard of care in small-cell lung cancer but with adverse events previously uncommon with solid tumor drugs.

Clinical trial results were presented at the recent World Conference on Lung Cancer (WCLC) for Imdelltra and two other DLL3...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from R&D

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers